(Q21144599)

English

Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes

scientific article

Adjunctive Atypical Antipsychotic Treatment for Major Depressive Disorder: A Meta-Analysis of Depression, Quality of Life, and Safety Outcomes

In more languages

Statements

scholarly article

0 references

1 reference

based on heuristic

inferred from title

Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes (English)

0 references

0 references

quality of life

1 reference

based on heuristic

inferred from title

major depressive disorder

1 reference

based on heuristic

inferred from title

6

object named as

Alexander C Tsai

author given names

Alexander C

author last names

Tsai

1 reference

PubMed publication ID

16 August 2022

author name string

Glen I Spielmans

1

author given names

Glen I

author last names

Spielmans

1 reference

PubMed publication ID

16 August 2022

Margit I Berman

2

author given names

Margit I

author last names

Berman

1 reference

PubMed publication ID

16 August 2022

Eftihia Linardatos

3

author given names

Eftihia

author last names

Linardatos

1 reference

PubMed publication ID

16 August 2022

Nicholas Z Rosenlicht

4

author given names

Nicholas Z

author last names

Rosenlicht

1 reference

PubMed publication ID

16 August 2022

Angela Perry

5

author given names

Angela

author last names

Perry

1 reference

PubMed publication ID

16 August 2022

language of work or name

0 references

publication date

2013

0 references

0 references

10

0 references

3

0 references

e1001403

0 references

copyright license

Creative Commons Attribution 4.0 International

12 March 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Increasing off-label use of antipsychotic medications in the United States, 1995-2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

19 March 2017

Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

19 March 2017

Efficacy of antidepressants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

19 March 2017

Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

19 March 2017

Efficacy of antidepressants in adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

19 March 2017

A rating scale for depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

19 March 2017

Simpson's paradox and calculation of number needed to treat from meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

19 March 2017

Second-generation antipsychotics for major depressive disorder and dysthymia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

19 March 2017

Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

19 March 2017

Measuring inconsistency in meta-analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

19 March 2017

Quantifying heterogeneity in a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

19 March 2017

Meta-analysis in clinical trials

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

19 March 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

12 September 2017

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

19 March 2017

Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

19 March 2017

Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

19 March 2017

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

19 March 2017

Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

19 March 2017

An assessment of clinically useful measures of the consequences of treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

19 March 2017

Systematic review of the empirical evidence of study publication bias and outcome reporting bias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

7 April 2017

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

7 April 2017

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

7 April 2017

Use of antipsychotics among older residents in VA nursing homes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

12 September 2017

Meta-analyses and Forest plots using a microsoft excel spreadsheet: step-by-step guide focusing on descriptive data analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

12 September 2017

Maintenance treatment study designs in bipolar disorder: do they demonstrate that atypical neuroleptics (antipsychotics) are mood stabilizers?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

12 September 2017

Quality of life: the ultimate outcome measure of interventions in major depressive disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

12 September 2017

A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

12 September 2017

The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

12 September 2017

Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

12 September 2017

National patterns in antidepressant medication treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

12 September 2017

Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

12 September 2017

Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

12 September 2017

The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

12 September 2017

Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

12 September 2017

A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

12 September 2017

Selective serotonin reuptake inhibitors for unipolar depression: a systematic review of classic long-term randomized controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

12 September 2017

Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

12 September 2017

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

12 September 2017

Clinical trials and the response rate illusion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

12 September 2017

SSRI-associated sexual dysfunction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

12 September 2017

Report by the ACNP Task Force on response and remission in major depressive disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

12 September 2017

Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

12 September 2017

Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

12 September 2017

Social functioning: should it become an endpoint in trials of antidepressants?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

12 September 2017

Quality of life assessments in major depressive disorder: a review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

12 September 2017

SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

12 September 2017

Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

27 September 2017

The measurement of disability.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

27 September 2017

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

30 May 2018

Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

30 May 2018

Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

19 June 2018

Off-label use of antipsychotic medications in the department of Veterans Affairs health care system

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001403

21 January 2018

Underrecognition of clinically significant side effects in depressed outpatients.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001403

21 January 2018

Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001403

21 January 2018

CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001403

21 January 2018

A novel augmentation strategy for treating resistant major depression

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001403

21 January 2018

A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study).

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001403

21 January 2018

Risperidone for treatment-refractory major depressive disorder: a randomized trial

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001403

21 January 2018

Aripiprazole in refractory depression?

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001403

21 January 2018

Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001403

21 January 2018

Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001403

21 January 2018

Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001403

21 January 2018

Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001403

21 January 2018

Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001403

21 January 2018

Meta-analysis of trials comparing antidepressants with active placebos.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001403

21 January 2018

Blinded trials taken to the test: an analysis of randomized clinical trials that report tests for the success of blinding.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001403

21 January 2018

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001403

21 January 2018

Unclear clinical significance of findings in adjunctive aripiprazole for major depressive disorder: comments on article by Marcus et al.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001403

21 January 2018

Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled st

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001403

21 January 2018

Prevention of recurrent postpartum depression: a randomized clinical trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595214

29 November 2018

The inventory for depressive symptomatology (IDS): Preliminary findings

1 reference

https://pubmed.ncbi.nlm.nih.gov/23554581

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure

1 reference

https://pubmed.ncbi.nlm.nih.gov/23554581

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double-blindness procedures, rater blindness, and ratings of outcome. Observations from a controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23554581

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23554581

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assuring That Double-Blind Is Blind

1 reference

https://pubmed.ncbi.nlm.nih.gov/23554581

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q21144599&oldid=1865242757"